Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc-PSMA-I&S Radio-guided Surgery in Prostate Cancer
NCT04832958Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium Tc-99m PSMA I&S in prostate cancer (PCa), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Rate of lymph node invasion at 12 weeks. Started May 2021; status: completed.
02
Drugs
technetium Tc-99m PSMA I&S
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04832958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832958.